Why SBFM must be accumulated for the long term
Post# of 226
Posted On: 11/16/2012 10:46:06 PM
Why SBFM must be accumulated for the long term
Topoisomerase II is an enzyme that aggressive cancer cells make too much of. When the cell is able to make a lot of the Topoisomerase II
enzyme, it becomes able to proliferate and metastasize; so, if you can inhibit or destroy the activity of Topoisomerase II, you would then be
able to prevent cancer cells from spreading.
Our Proprietary Technology
Our licensor, Advanomics Corporation, has developed a way to replace the diester bond with a Carbon-Difluoride bond which acts as a perfect diester isostere. This technology allows us to create a large variety of therapeutic compounds that are completely stable and often more active than the original drugs. This unique capability allowed us to create our Lead Compound, Adva-27a, an effective and highly specific Topoisomerase II (Top2) Inhibitor.
Our Carbon-Difluoride Technology is covered by issued and pending patents filed under PCT/FR2003/002330 and PCT/FR2007/000697
Adva-27a is 16-times more effective at killing multidrug resistant breast cancer cells than Etoposide, the drug currently in use.
Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.
Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies.
Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.
Adva-27a is an excellent inhibitor of Topoisomerase ll with an IC50 of only 13.7 micromolar.
Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats
Adva-27a's initial indication will be multidrug resistant breast cancer for which there are little or no treatment options
Our Published Data show that Adva-27a is a true Topoisomerase ll Inhibitor and is significantly more effevtive at killing aggressive cancer cells than Etoposide, the current drug of choice.
Check out SBFM's drug Adva-27a (27a) vs the leading chem drug Etoposide (2) - results are better in every category except two. And in the multi drug resistance breast cancer category (MCF7R) it's over 3x more effective.
Unique Features of Adva-27a
* Adva-27a can be taken orally.
* Adva-27a is not a so-called me-too drug; our technology is unique. Adva-27a will be the only Topoisomerase ll Inhibitor on the Market.
* Adva-27a's initial indication will be multi-drug resistant breast cancer. Adva-27a can be used to treat other Top2 Positive Cancer Types (Prostate, Colon, Lung, Stomach, Ovarian).
The U.S. Food and Drug Administration's (FDA) approval process is likely to be granted fast-track designation since Adva-27a has the potential to help terminally ill patients with no other therapy options and can be used to treat multiple cancer types. As a result of its unique capabilities, versatility and lack of competition, Sunshine Biopharma's Lead Compound could significantly exceed the typical Revenues generated from anti-cancer drugs, which in general reach $1 Billion in annual sales within two or three years of FDA Approval.
Sunshine Biopharma Drug Pipeline
Adva-27a - Completed Preclinicals
Compound for Small-Cell Lung Cancer - In Preclinical Studies
A Third RNAi-Based Drug
Topoisomerase II is an enzyme that aggressive cancer cells make too much of. When the cell is able to make a lot of the Topoisomerase II
enzyme, it becomes able to proliferate and metastasize; so, if you can inhibit or destroy the activity of Topoisomerase II, you would then be
able to prevent cancer cells from spreading.
Our Proprietary Technology
Our licensor, Advanomics Corporation, has developed a way to replace the diester bond with a Carbon-Difluoride bond which acts as a perfect diester isostere. This technology allows us to create a large variety of therapeutic compounds that are completely stable and often more active than the original drugs. This unique capability allowed us to create our Lead Compound, Adva-27a, an effective and highly specific Topoisomerase II (Top2) Inhibitor.
Our Carbon-Difluoride Technology is covered by issued and pending patents filed under PCT/FR2003/002330 and PCT/FR2007/000697
Adva-27a is 16-times more effective at killing multidrug resistant breast cancer cells than Etoposide, the drug currently in use.
Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.
Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies.
Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.
Adva-27a is an excellent inhibitor of Topoisomerase ll with an IC50 of only 13.7 micromolar.
Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats
Adva-27a's initial indication will be multidrug resistant breast cancer for which there are little or no treatment options
Our Published Data show that Adva-27a is a true Topoisomerase ll Inhibitor and is significantly more effevtive at killing aggressive cancer cells than Etoposide, the current drug of choice.
Check out SBFM's drug Adva-27a (27a) vs the leading chem drug Etoposide (2) - results are better in every category except two. And in the multi drug resistance breast cancer category (MCF7R) it's over 3x more effective.
Unique Features of Adva-27a
* Adva-27a can be taken orally.
* Adva-27a is not a so-called me-too drug; our technology is unique. Adva-27a will be the only Topoisomerase ll Inhibitor on the Market.
* Adva-27a's initial indication will be multi-drug resistant breast cancer. Adva-27a can be used to treat other Top2 Positive Cancer Types (Prostate, Colon, Lung, Stomach, Ovarian).
The U.S. Food and Drug Administration's (FDA) approval process is likely to be granted fast-track designation since Adva-27a has the potential to help terminally ill patients with no other therapy options and can be used to treat multiple cancer types. As a result of its unique capabilities, versatility and lack of competition, Sunshine Biopharma's Lead Compound could significantly exceed the typical Revenues generated from anti-cancer drugs, which in general reach $1 Billion in annual sales within two or three years of FDA Approval.
Sunshine Biopharma Drug Pipeline
Adva-27a - Completed Preclinicals
Compound for Small-Cell Lung Cancer - In Preclinical Studies
A Third RNAi-Based Drug
(0)
(0)